87 results about "Endopeptidase" patented technology

The present disclosure provides compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; the use of such compounds and salts for the treatment or prevention of prolyl endopeptidase fibroblast activation protein (FAP) mediated disorders; kits comprising such compounds and salts; and processes for preparing such compounds and salts. # imgabs0 #

The invention provides a preparation method of yak bone collagen peptide, a composition for promoting skeletal development and application of the composition, and relates to the technical field of health food. The preparation method comprises the following steps: carrying out ultrasonic pretreatment on yak bones, and degreasing through supercritical CO2 to obtain a degreased product; mixing the degreased product with a fishy smell removing agent to obtain a fishy smell removing product; the fishy smell removing agent is an aqueous solution of a plant extract; the plant extract is selected from at least one of amomum tsao-ko extract, turmeric extract, green tea extract or momordica grosvenori extract; the fishy smell removal product is subjected to an enzymatic hydrolysis reaction through an immobilized compound enzyme reactor, wherein the compound enzyme is prolyl endopeptidase, papain and ficin; obtaining a crude product; carrying out ultrafiltration by adopting a filter membrane with the molecular weight cut-off of 1kDa, and adsorbing through macroporous resin. The yak bone collagen peptide and the composition prepared by the invention can obviously improve the body length, promote the skeletal development and promote the secretion of growth hormone, and meet the growth requirements of children.

The invention discloses an aspergillus oryzae engineering bacterium as well as a construction method and application of the aspergillus oryzae engineering bacterium, and relates to the technical field of genetic engineering. The method comprises the following steps of: (a) connecting and fusing an open reading frame of an endogenous gene with a fungal laccase copper oxidoreductase structural domain and a target heterologous protein gene through a dual-basic amino acid endopeptidase cleavage site gene; or connecting and fusing an open reading frame of an endogenous gene with a multi-copper oxidase structural domain and a target heterologous protein gene through a dual-basic amino acid endopeptidase cleavage site gene; and (b) at least one of a gene Aovps10, a gene AosedD and a gene Aoemp47 is knocked out. The aspergillus oryzae engineering bacterium provided by the invention can realize high-efficiency expression of the heterologous protein, and the extracellular yield of the heterologous protein is obviously improved.

The invention relates to the technical field of genetic engineering, and discloses an engineering bacterium for high-yield production of D-pantothenic acid based on sugar uptake regulation and a preparation method of the engineering bacterium. The method comprises the following steps: firstly, stabilizing an RNAP promoter open complex formed on an rRNA (Ribonucleic Acid) gene by intensively expressing a necessary global regulation transcription factor CarD of mycobacterium neoaurum; secondly, performing enhanced expression on mycobacterium neoaurum Rpf / Sps family protein RpfB which serves as a resuscitation promoting factor to play a role and catalyze peptidoglycan synthesis to accelerate cell wall growth; meanwhile, the inactivated cell wall lipoprotein Lpp accumulates the outer membrane vesicles; in addition, lipoprotein NlpI responsible for adjusting the activity of endopeptidase MopS and PBP4 is deleted, and the super vesicles are generated; in addition, the mutant membrane lipid asymmetric pathway protein MlaE disturbs the homeostasis of the outer membrane and increases the formation of vesicles; in addition, the membrane anchoring protein TolA is destroyed to improve the membrane permeability; and finally, the escherichia coli gene engineering strain with greatly improved D-pantothenic acid production performance is obtained.

The invention relates to a method for reducing the anaphylaxis of natural latex by multi-enzyme cascade catalysis of rubber protein. The invention relates to the technical field of catalysis of rubber protein hydrolysis, in particular to a method for reducing the anaphylaxis of natural latex by thoroughly hydrolyzing rubber protein through multi-enzyme cascade catalysis. The method for reducing the anaphylaxis of the natural latex by catalyzing the rubber protein through the synergistic effect of multiple enzymes from the perspective of industrial production comprises the following steps: adding an enzyme A and an enzyme B into the natural latex for reaction so as to reduce the anaphylaxis of the natural latex, the enzyme A is alkaline protease; and the B enzyme is at least one of aminopeptidase, carboxypeptidase B, carboxypeptidase A and carboxypeptidase Y. According to the method disclosed by the invention, the enzyme A-endopeptidase and the enzyme B-exopeptidase are subjected to multi-enzyme-stage combined treatment and concerted catalysis, so that the enzyme A-endopeptidase and the enzyme B-exopeptidase are completely hydrolyzed or are completely hydrolyzed into more amino acid substances and short-chain peptides (oligopeptides) as far as possible, and the amino acid substances and the short-chain peptides (oligopeptides) are retained in latex. Protein is highly hydrolyzed into amino acid with higher safety, so that the possibility of I-type anaphylactic reaction caused by protein allergens is greatly reduced or even eliminated.

A method for increasing the softness and relaxation of dough, the method comprising a) adding at least one endopeptidase having at least 60% identity to SEQ ID NO: 1 or SEQ ID NO: 2 to flour or to a dough comprising flour, wherein L-cysteine ​​and / or sodium metabisulfite is not added to the dough; b) kneading the dough; and c) forming the dough into an edible product.

A method for increasing the softness and the relaxation of a dough comprising a) adding at least one endopeptidase having at least 60% identity to SEQ ID NO:1 or SEQ ID NO:2 to flour or to a dough comprising a flour, wherein no L-cystein and / or sodium metabisulfite is added to the dough; b) kneading the dough; and c) making the dough into an edible product.

The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and / or human soluble endopeptidase (hSEP), and endothelin convertase (ECE), inhibitory activity. The compounds of this invention are useful for the preparation of pharmaceutical compositions to reduce harmful effects of symptomless progressive disseminated perfusion deficiency of organs, or parts thereof, that may be suggestive of systemic diseases.

The invention relates to application of an asparagine endopeptidase inhibitor in preparation of a medicine for improving insulin resistance. According to the application, starting from inhibiting the aging driving factor AEP, the AEP inhibitor is tried to be applied to the research of insulin resistance for the first time, and the AEP inhibitor is found to be capable of remarkably improving glucose tolerance and insulin sensitivity. Therefore, the invention provides the application of the asparagine endopeptidase inhibitor in preparation of the medicine for improving insulin resistance. Experiments prove that the AEP inhibitor not only can significantly enhance insulin sensitivity of old mice and improve glucose tolerance, but also can reduce serum low-density lipoprotein cholesterol and lactic dehydrogenase levels, shows multiple improvement effects on glucose metabolism and lipid metabolism, and also can be used for preparing the AEP inhibitor. After long-term administration, obvious toxic and side effects are not found in pathological examinations of blood routine examination, urine routine examination, heart, liver, spleen, lung, kidney and other important organs, so that the traditional Chinese medicine composition is proved to have good safety and is suitable for long-term intervention of chronic diseases.

The present invention aims to provide a marker for diagnosing non-alcoholic fatty liver disease (NAFLD). The above-mentioned problem has been solved by a marker for diagnosing non-alcoholic fatty liver disease (NAFLD), said marker being at least one protein selected from the group consisting of endopeptidases, hydrolases, calcium ion-binding proteins, cytoskeletal proteins, transferases, receptor-binding proteins, phosphatases, antigen-binding proteins, RNA-binding proteins, reductases, and cadherin-binding proteins, or a gene encoding said protein.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

To provide a technology to suppress unpleasant odors and tastes of beans.SOLUTION: An unpleasant odor and taste suppressing agent contains exopeptidase as an active ingredient and suppresses one or more of bean odors, bitterness of beans, and harsh taste of beans. According to the present invention, unpleasant odors and taste originating from beans can be suppressed through a simple process of contacting beans or their processed products with exopeptidase, endopeptidase, and / or asparaginase, thereby enhancing the commercial value of food products containing beans.SELECTED DRAWING: Figure 2

The invention discloses an endopeptidase mutant with improved self-degradation resistance and a preparation method thereof. The endopeptidase mutant is not obviously self-degraded in a proper preservation buffer solution after being kept at 25 DEG C for 24 hours, while the wild type endopeptidase can obviously generate four self-degraded peptide fragments after being preserved for 6 hours under the same condition; the endopeptidase mutant still keeps catalytic activity higher than that of wild type endopeptidase under the condition of a precursor with improved self-degradation resistance, and has obvious advantages in various aspects. According to the invention, the stable endopeptidase can be obtained at a lower cost, and the endopeptidase can be better applied to the field of biological medicines.

[Problem] To provide a novel compound for use as a substrate for evaluating the activity of γ-D-glutamyl-L-lysyl endopeptidase and a method for evaluating the activity of γ-D-glutamyl-L-lysyl endopeptidase using the compound. [Solution] The present invention relates to a compound represented by formula (1) or a stereoisomer thereof, which is useful as a substrate for evaluating the activity of γ-D-glutamyl-L-lysyl endopeptidase. [Formula 1] (In formula (1), A represents formula (2) or an amino-protecting group, and Z represents a detection group which becomes detectable upon liberation.) [Formula 2] (In formula (2), B represents a hydrogen atom, an optionally substituted N-acetyl-muramoyl group, or an acyl- or amino-protecting group.)

FISH PROTEIN HYDROLYSATE AND APPLICATIONS IN FARM ANIMALS The present invention relates to a protein hydrolysate originating from fish tissues or cartilages rich in protein, in particular collagen, and its applications in the feeding and welfare of farm animals, in particular pigs and poultry. In particular, the invention relates to a hydrolysate obtained by enzymatic digestion using an endopeptidase enzyme, said hydrolysate being characterized in that it has a protein fraction having a molecular profile with the following distribution: between 15 and 60% of peptides with a molecular weight of between 1000 and 5000 Da, between 20 and 40% of peptides with a molecular weight of between 500 and 1000 Da, between 10 and 40% of peptides with a molecular weight of between 150 and 500 Da, between 1 and 10% of peptides with a molecular weight of between 1000 and 50 ... molecular weight less than 150 Da. Fig. 2

The invention relates to medical application of an asparagine endopeptidase inhibitor in mitral valve mucus-like degeneration, and belongs to the technical field of biological medicine. The invention provides an application of an asparagine endopeptidase inhibitor in preparation of a medicine for treating mitral valve mucus-like degeneration. The invention relates to an application in preparation of a medicine for relieving mitral valve insufficiency. The invention relates to application in preparation of a medicine for inhibiting mitral valve thickening. The invention also discloses an application of the LGMN in preparing a medicine for treating mitral valve mucus-like degeneration by inhibiting the LGMN secreted by the in-situ macrophages. According to the application disclosed by the invention, the LGMN secreted by the macrophages is subjected to targeted antagonism, so that the myofibroblast transformation of the valvular interstitial cells is delayed, and a new target spot and a treatment path are provided for precise treatment of the mitral valve mucus-like degeneration.

Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5, and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

The invention relates to a T cell intracellular antigen TIA1 truncation body protein tTIA1 and application thereof, and the T cell intracellular antigen TIA1 truncation body protein tTIA1 is tTIA1-N with an amino acid sequence as shown in SEQ ID NO.1 and / or tTIA1-C with an amino acid sequence as shown in SEQ ID NO.2. The T cell intracellular antigen TIA1 truncation body protein tTIA1 is a TIA1-N protein with an amino acid sequence as shown in SEQ ID NO.1. The tTIA1-N and the tTIA1-C are generated by carrying out targeted enzyme digestion on an intracellular antigen TIA1 of a T cell by virtue of asparagine endopeptidase AEP, so that the tTIA1-N and the tTIA1-C have relatively high sensitivity and accuracy and a very strong application prospect.

A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutral endopeptidase (NEP) inhibitor or a prodrug thereof, particularly a NEP inhibitor comprising a skeleton of γ-amino-δ-biphenyl-α-methylalkanoic acid or ester, such as sacubitril. Also provided are intermediates for preparing formula (10) or formula (10-a). Raw materials of the process route are cheap, the operation is simple and convenient, the production cost is low, and the method is suitable for industrial production

Compounds having the structure of formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is as defined herein, compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts for treating or preventing prolyl endopeptidase fibroblast activation protein (FAP) mediated conditions; kits comprising such compounds and salts; and methods for preparing such compounds and salts. [Formula 1] JPEG2025525344000321.jpg56128

The invention provides an application of recombinant DL-endopeptidase and a metabolite thereof in preparation of a medicine for preventing late-onset septicemia of a premature infant, and solves the technical problems of poor prevention effect, obvious side effect, limited clinical applicability and the like of the late-onset septicemia of the premature infant in the field of neonatal intensive care medicine for a long time. A brand-new and reliable technical support is provided for prevention and control of late-onset septicemia of premature infants, and technical innovation and development in the field of neonatal infectious disease prevention are promoted.

The application provides a polypeptide with angiotensin converting enzyme inhibitory activity and a preparation method and application thereof, and relates to the technical field of active peptide preparation. The abalone is pulverized, a complex enzyme is added for primary enzymolysis, and then a specific protease mixture containing prolyl endopeptidase, chymotrypsin and protease K is added for two-step enzymolysis, so that the obtained polypeptide solution has high ACE inhibitory activity. The obtained polypeptide is analyzed and screened to obtain polypeptides with amino acid sequences as shown in SEQ ID NO. 1-5. The polypeptide has high ACE inhibitory activity, and the IC 50 0.05mg / mL-0.40mg / mL, and therefore can play a blood pressure lowering effect as an angiotensin converting enzyme inhibitor.

When bacteria with different bacteriolysis targets are detected, it was necessary to lyse the individual bacteria separately with lysis solutions containing lysis enzymes suitable for each bacteriolysis target, resulting in a complicated and delayed bacteriolysis process. The purpose of this invention is to provide a new bacteriolysis method for lysing bacteria belonging to two or more species in a sample, making the bacteriolysis process more efficient and rapid.Provided is method for lysing a group of bacteria in the sample, comprising the step of lysing the group of bacteria in the sample in a mixture solution obtained by mixing the sample, a bacteriolysis enzyme, and a bacteriolysis aid, wherein the bacteriolysis enzyme includes at least one bacteriolysis enzyme selected from the group consisting of lysostaphin, lysozyme, acetyl glucosaminidase, and endopeptidase, and wherein the mixture solution has a pH of from 6.0 to 7.0 and an electrical conductivity of from 2.5 to 8.5 mS / cm, whereby bacteriolysis of two or more species of bacteria becomes possible.

The present invention relates to a solid state form of N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide, and to a method for preparing the same. Specifically, the invention discloses a solid state form of N-(2-(4-cyano thiazolidine-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide, and a preparation method of the solid state form. A corresponding pharmaceutical composition; their use in the treatment or prevention of prolyl endopeptidase fibroblast activation protein (FAP) mediated conditions; a kit; and a preparation method thereof.

The present invention relates to preparation of an acidified milk product using a transglutaminase and a trypsin-like or lysine-specific endopeptidase.

The invention discloses an application of DL-endopeptidase in preparation of a synergist of an immune checkpoint inhibitor, and the DL-endopeptidase has an amino acid sequence as shown in SEQ ID NO.1 or has a DNA (deoxyribonucleic acid) sequence as shown in SEQ ID NO.2. The invention further discloses a preparation method of the DL-endopeptidase. The application confirms that the DL-endopeptidase can be used as a synergist, can be combined with an immune examination inhibitor for use, is used for activating the immune state of a patient and improving the response of ICB, and is beneficial to expanding the applicable crowd of ICB.

An anhydrous composition comprising an endolysin derived from a Staphylococcus aureus phage and mannitol. The present invention relates to an anhydrous composition comprising (i) at least one endolysin derived from a Staphylococcus aureus phage; and (ii) mannitol, the endolysin comprising a protein sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of the reference amino acid sequences SEQ ID NO: 1 and SEQ ID NO: 2. It also relates to a composition comprising, in a physiologically acceptable medium, at least one anhydrous composition of the invention.It also covers the use of such a composition to prevent and / or treat a skin disorder related to Staphylococcus aureus colonization in an individual in need, and a non-therapeutic cosmetic process for the care of keratinous materials comprising at least one step of topical application of such a composition to said keratinous materials. Finally, it covers a process for stabilizing an endolysin derived from a Staphylococcus aureus phage. Figure for the abstract: None.

This invention discloses the use of Pv-PEP1 protein in the treatment of gluten-contaminated feed. The use of Pv-PEP1 protein or related biological materials in at least one of the following: A1) treating gluten-contaminated feed; A2) preparing a product for treating gluten-contaminated feed; wherein the amino acid sequence of said Pv-PEP1 protein comprises the sequence shown in SEQ ID No:4. The Pv-PEP1 protein of this invention exhibits a significantly superior degradation effect on gluten in contaminated feed compared to currently reported Aspergillus niger prolyl endopeptidase (AN-PEP) and similar commercially available products, demonstrating significant technical advantages and broad application prospects.

Compounds having the structure of formula (I) and their pharmaceutically acceptable salts are disclosed, wherein X 1 R 1 R 2 R 3 R 4 R 5 and R 6 This refers to: pharmaceutical compositions comprising such compounds and salts as defined in the specification; the use of such compounds and salts for the treatment or prevention of prolyl endopeptidase fibroblast activation protein (FAP)-mediated diseases; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts. Formula (I):